| Income Statement | 2025-09-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 1,111,797 | 728,867 | 607,494 | 872,287 |
| Cost of revenue (exclusive of amortization shown separately below) | 593,506 | 387,499 | 384,381 | 525,486 |
| Gross profit | 518,291 | 341,368 | 223,113 | 346,801 |
| Government support income | 193,267 | 173,271 | 133,640 | 126,128 |
| Selling, general and administrative expenses | 2,659,824 | 2,407,558 | 1,809,114 | 1,949,016 |
| Development and regulatory approval expenses | 486,169 | 358,351 | 506,944 | 948,752 |
| Depreciation and amortization | 303,378 | 301,978 | 305,177 | 300,422 |
| Impairment of long-lived assets | 261,780 | - | - | - |
| Total operating expenses | 3,711,151 | 3,067,887 | 2,621,235 | 3,198,190 |
| Realized foreign exchange loss | - | -113 | -750 | -51 |
| Loss from operations | -2,999,593 | -2,553,248 | -2,264,482 | -2,725,261 |
| Interest expense | 3,903 | 15,000 | 13,502 | 22,327 |
| Interest income | 8,504 | 17,687 | 21,937 | 52,840 |
| Total other income, net | 4,601 | 2,574 | 7,685 | 30,462 |
| Net loss | -2,994,992 | -2,550,674 | -2,256,797 | -2,694,799 |
| Net loss attributable to non-controlling interest | -11,986 | -7,148 | -7,327 | -9,166 |
| Net loss attributable to intelligent bio solutions inc | -2,983,006 | -2,543,526 | -2,249,470 | -2,685,633 |
| Net loss per share, basic | -0.35 | -0.44 | -0.5 | -0.7 |
| Net loss per share, diluted | -0.35 | -0.44 | -0.5 | -0.7 |
| Weighted average shares outstanding, basic | 8,546,934 | 5,771,911 | 4,535,815 | 3,811,090 |
| Weighted average shares outstanding, diluted | 8,546,934 | 5,771,911 | 4,535,815 | 3,811,090 |
INTELLIGENT BIO SOLUTIONS INC. (INBS)
INTELLIGENT BIO SOLUTIONS INC. (INBS)